로딩 중...
52주 최고가 대비 94.3% 위치
Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It also provides the nCounter analysis system services. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.
SEC 13F 공시 기준 · 2026-Q1
SEC 13F 공시 기준 데이터입니다. 실제 현재 보유 현황과 다를 수 있으며, 투자 자문·권유·추천이 아닙니다.
| 재무 항목 | 2021년 | 2022년 | 2023년 | 2024년 | 2025년 |
|---|---|---|---|---|---|
| 주요 재무실적 (USD) | |||||
| 매출액 | - | $296.5M | $361.1M | $445.8M | $517.1M |
| 영업이익 | - | $-35.3M | $-17.4M | $19.5M | $78.3M |
| 당기순이익 | - | $-36.6M | $-74.4M | $24.1M | $66.4M |
| 잉여현금흐름 (FCF) | - | $-1.0M | $34.3M | $63.8M | $126.6M |
| 수익성 비율 | |||||
| 영업이익률 | - | -11.9% | -4.8% | 4.4% | 15.1% |
| 순이익률 | - | -12.3% | -20.6% | 5.4% | 12.8% |
| ROE (자기자본이익률) | - | -3.4% | -7.1% | 2.1% | 5.1% |
| ROA (자산이익률) | - | -3.2% | -6.7% | 1.9% | 4.7% |
| 성장성 비율 | |||||
| 매출 성장률 (YoY) | - | - | 21.8% | 23.5% | 16.0% |
| EPS 성장률 (YoY) | - | - | -100.0% | 130.4% | 164.5% |
| 투자 지표 & 가치배수 | |||||
| PER (주가수익배수) | - | - | - | 146.7x | 46.4x |
| PBR (주가순자산배수) | - | 1.9x | 1.9x | 3.1x | 2.3x |
| PSR (주가매출배수) | - | 6.8x | 5.5x | 8.1x | 5.9x |
| FCF Yield | - | -0.1% | 1.7% | 1.8% | 4.2% |
| 재무 건전성 (안정성) | |||||
| 부채비율 (D/E) | - | 0.01 | 0.01 | 0.04 | 0.03 |
| 유동비율 | - | 3.97 | 4.66 | 4.73 | 8.15 |
MOLINA HEALTHCARE INC
$179.86
$9.4B